To determine whether BRD9 is important for AML viability through the action of the bromodomain, we performed growth assays over a time course of treatment with I-BRD9, a competitive inhibitor specific to the bromodomain of BRD9 (74). The gene discussed is BRD9; the disease is acute myeloid leukemia.